diabetic kidney disease
Endocrinology · 2023–2023
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| finerenone Treatment of chronic kidney disease in patients with type 2 diabetes mellitus (diabetic kidney disease) with eGFR >25 mL/min/1.73 m² and UACR ≥200 mg/g, in… | Mar 2023 | Recommended with restriction | input received Kidney Health Australia |
Who spoke
Kidney Health Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.